Author + information
- Savitree Thummasorna,b,
- Krekwit Shinlapawittayatorna,b,
- Siriporn Chattipakorna,b and
- Nipon Chattipakorna,b
Background: Low-dose Humanin analogue (HNG) given prior to cardiac ischemia exerts cardioprotection against ischemia/reperfusion (I/R) injury, but failed to do so when applied during ischemia. However, in a clinical setting, patients can only be treated after the onset of ischemia. We hypothesized that high-dose HNG given after the ischemic onset exerts cardioprotection against I/R injury via reducing cardiac mitochondrial dysfunction.
Methods: Male Wistar rats were randomly divided into 6 groups (n=6/group). In the first 3 groups, HNG at various doses (84, 168 and 252 μg/kg) were intravenously (IV) injected at 15 min after left anterior descending coronary (LAD) occlusion (IH84, IH168 and IH252, respectively). In group 4, normal saline was IV injected instead of HNG. In group 5, HNG (252 μg/kg) was IV injected at the reperfusion onset (ReH252). In group 6, rats were subjected to sham operation (Sham). I/R injury was induced by 30-min LAD occlusion, followed by 120-min reperfusion.
Results: Of all treatments, only 252 μg/kg HNG given during the ischemic period increased HN levels in the ischemic myocardium (Figure panel A), decreased infarct size (panel B) and arrhythmia score (panel C), improved cardiac mitochondrial function (panel D), and reduced pro-apoptotic proteins (Bax and Cytochrome C).
Conclusions: High-dose HNG given during ischemic period effectively provides cardioprotection against I/R injury via reducing cellular apoptosis and decreasing cardiac mitochondrial dysfunction.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Antithrombotic Therapy in Ischemic Heart Disease
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1252-312
- 2017 American College of Cardiology Foundation